- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated   in the first half of 2024 - - CX-2051 (EpCAM-directed ADC) comprehensive preclinical profile presented at 14 th Annual World ADC Conference ; IND filing on track for year-end - - Updated CX-801 (conditionally

SOUTH SAN FRANCISCO, Calif. , Nov. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in November.

SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report third quarter financial results on Tuesday, November 7, 2023, after the close of U.S.

- IND filing for CX-801 anticipated by the end of 2023 - SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that preclinical data supporting CX-801, its

- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload - - Preclinical data demonstrate a favorable predicted therapeutic index and efficacy across multiple EpCAM-expressing tumors, including

SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in September. H.C.

SOUTH SAN FRANCISCO, Calif. , Aug. 10, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the H.C.

- CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 -                          - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 - - Management to hold conference call today at 5 p.m.

SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report second quarter financial results on Tuesday, August 8, 2023, after the close of U.S.

SOUTH SAN FRANCISCO, Calif. , July 20, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on July 19, 2023 , the Company granted its recently appointed Senior Vice President, Chief Medical